gastroenterology
IBD

Thrombosis restriction for JAK inhibitor in ulcerative colitis


The US Food and Drug Administration has restricted the use of high-dose tofacitinib (Xeljanz) in ulcerative colitis and added a black box warning to the label after researchers found a link between the 10 mg dose and a higher risk of pulmonary embolism (PE) and death in patients with rheumatoid arthritis (RA). In a safety ...

Already a member?

Enter your email to keep reading.


OR